Preclinical Studies of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Preclinical Studies of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model. ASH 2013.